These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 17683157)

  • 1. Improved efficacy of alphavbeta3-targeted albumin conjugates by conjugation of a novel auristatin derivative.
    Temming K; Meyer DL; Zabinski R; Senter PD; Poelstra K; Molema G; Kok RJ
    Mol Pharm; 2007; 4(5):686-94. PubMed ID: 17683157
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of RGD-targeted albumin carriers for specific delivery of auristatin E to tumor blood vessels.
    Temming K; Meyer DL; Zabinski R; Dijkers EC; Poelstra K; Molema G; Kok RJ
    Bioconjug Chem; 2006; 17(6):1385-94. PubMed ID: 17105215
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enhanced activity of monomethylauristatin F through monoclonal antibody delivery: effects of linker technology on efficacy and toxicity.
    Doronina SO; Mendelsohn BA; Bovee TD; Cerveny CG; Alley SC; Meyer DL; Oflazoglu E; Toki BE; Sanderson RJ; Zabinski RF; Wahl AF; Senter PD
    Bioconjug Chem; 2006; 17(1):114-24. PubMed ID: 16417259
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel peptide linkers for highly potent antibody-auristatin conjugate.
    Doronina SO; Bovee TD; Meyer DW; Miyamoto JB; Anderson ME; Morris-Tilden CA; Senter PD
    Bioconjug Chem; 2008 Oct; 19(10):1960-3. PubMed ID: 18803412
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development of potent monoclonal antibody auristatin conjugates for cancer therapy.
    Doronina SO; Toki BE; Torgov MY; Mendelsohn BA; Cerveny CG; Chace DF; DeBlanc RL; Gearing RP; Bovee TD; Siegall CB; Francisco JA; Wahl AF; Meyer DL; Senter PD
    Nat Biotechnol; 2003 Jul; 21(7):778-84. PubMed ID: 12778055
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interest of RGD-containing linear or cyclic peptide targeted tetraphenylchlorin as novel photosensitizers for selective photodynamic activity.
    Frochot C; Di Stasio B; Vanderesse R; Belgy MJ; Dodeller M; Guillemin F; Viriot ML; Barberi-Heyob M
    Bioorg Chem; 2007 Jun; 35(3):205-20. PubMed ID: 17223161
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeted cancer therapy: conferring specificity to cytotoxic drugs.
    Chari RV
    Acc Chem Res; 2008 Jan; 41(1):98-107. PubMed ID: 17705444
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Delivery of the p38 MAPkinase inhibitor SB202190 to angiogenic endothelial cells: development of novel RGD-equipped and PEGylated drug-albumin conjugates using platinum(II)-based drug linker technology.
    Temming K; Lacombe M; van der Hoeven P; Prakash J; Gonzalo T; Dijkers EC; Orfi L; Kéri G; Poelstra K; Molema G; Kok RJ
    Bioconjug Chem; 2006; 17(5):1246-55. PubMed ID: 16984135
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Precision Chemoradiotherapy for HER2 Tumors Using Antibody Conjugates of an Auristatin Derivative with Reduced Cell Permeability.
    Hingorani DV; Doan MK; Camargo MF; Aguilera J; Song SM; Pizzo D; Scanderbeg DJ; Cohen EEW; Lowy AM; Adams SR; Advani SJ
    Mol Cancer Ther; 2020 Jan; 19(1):157-167. PubMed ID: 31597712
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Orthogonal assembly of a designed ankyrin repeat protein-cytotoxin conjugate with a clickable serum albumin module for half-life extension.
    Simon M; Frey R; Zangemeister-Wittke U; Plückthun A
    Bioconjug Chem; 2013 Nov; 24(11):1955-66. PubMed ID: 24168270
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of drug loading on the antitumor activity of a monoclonal antibody drug conjugate.
    Hamblett KJ; Senter PD; Chace DF; Sun MM; Lenox J; Cerveny CG; Kissler KM; Bernhardt SX; Kopcha AK; Zabinski RF; Meyer DL; Francisco JA
    Clin Cancer Res; 2004 Oct; 10(20):7063-70. PubMed ID: 15501986
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthesis and Biological Evaluation of RGD and isoDGR-Monomethyl Auristatin Conjugates Targeting Integrin α
    Raposo Moreira Dias A; Bodero L; Martins A; Arosio D; Gazzola S; Belvisi L; Pignataro L; Steinkühler C; Dal Corso A; Gennari C; Piarulli U
    ChemMedChem; 2019 May; 14(9):938-942. PubMed ID: 30840356
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Engineered antibody-drug conjugates with defined sites and stoichiometries of drug attachment.
    McDonagh CF; Turcott E; Westendorf L; Webster JB; Alley SC; Kim K; Andreyka J; Stone I; Hamblett KJ; Francisco JA; Carter P
    Protein Eng Des Sel; 2006 Jul; 19(7):299-307. PubMed ID: 16644914
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeted Drug Delivery with an Integrin-Binding Knottin-Fc-MMAF Conjugate Produced by Cell-Free Protein Synthesis.
    Currier NV; Ackerman SE; Kintzing JR; Chen R; Filsinger Interrante M; Steiner A; Sato AK; Cochran JR
    Mol Cancer Ther; 2016 Jun; 15(6):1291-300. PubMed ID: 27197305
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PR_b-targeted PEGylated liposomes for prostate cancer therapy.
    Demirgöz D; Garg A; Kokkoli E
    Langmuir; 2008 Dec; 24(23):13518-24. PubMed ID: 18954096
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development and properties of beta-glucuronide linkers for monoclonal antibody-drug conjugates.
    Jeffrey SC; Andreyka JB; Bernhardt SX; Kissler KM; Kline T; Lenox JS; Moser RF; Nguyen MT; Okeley NM; Stone IJ; Zhang X; Senter PD
    Bioconjug Chem; 2006; 17(3):831-40. PubMed ID: 16704224
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cell-penetrating peptide-conjugated XIAP-inhibitory cyclic hexapeptides enter into Jurkat cells and inhibit cell proliferation.
    Sasaki Y; Minamizawa M; Ambo A; Sugawara S; Ogawa Y; Nitta K
    FEBS J; 2008 Dec; 275(23):6011-21. PubMed ID: 19016849
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lysosomal trafficking and cysteine protease metabolism confer target-specific cytotoxicity by peptide-linked anti-CD30-auristatin conjugates.
    Sutherland MS; Sanderson RJ; Gordon KA; Andreyka J; Cerveny CG; Yu C; Lewis TS; Meyer DL; Zabinski RF; Doronina SO; Senter PD; Law CL; Wahl AF
    J Biol Chem; 2006 Apr; 281(15):10540-7. PubMed ID: 16484228
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Contribution of linker stability to the activities of anticancer immunoconjugates.
    Alley SC; Benjamin DR; Jeffrey SC; Okeley NM; Meyer DL; Sanderson RJ; Senter PD
    Bioconjug Chem; 2008 Mar; 19(3):759-65. PubMed ID: 18314937
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Albumin as a drug carrier: design of prodrugs, drug conjugates and nanoparticles.
    Kratz F
    J Control Release; 2008 Dec; 132(3):171-83. PubMed ID: 18582981
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.